Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.3
Journals
Nanomaterials
Special Issues
Nanomedicine in Cancers
share announcement

Nanomedicine in Cancers

A special issue of Nanomaterials (ISSN 2079-4991). This special issue belongs to the section "Biology and Medicines".

Deadline for manuscript submissions: 20 August 2024 | Viewed by 3379

Special Issue Editor

Prof. Dr. Lisheng Wang

E-Mail Website
Guest Editor
Department of Biochemistry, Microbiology and Immunology Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Interests: cancer stem cells; breast cancer; nanoparticles; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nanomedicine holds great potential in anticancer drug/nucleotide/protein delivery, specific targeting, assessment of treatment responses, cancer vaccine, and cancer immunotherapy. A wide range of nanomaterials based on organic, inorganic, lipid, glycan compounds, synthetic polymers, molecularly imprinted polymers, and extracellular vesicles have been used for the development of new cancer therapeutics. Considerable nanoparticle platforms have been developed towards clinical applications, and some nanomaterials have been approved and used in patients. Nanomedicine has become one of the main driving forces in the field to change the cancer research landscapes, advance cancer treatment, and potentially improve patient outcomes.

This Special Issue welcomes contributions devoted to the design, characterization, and application of novel nanomedicine using different nanomaterial platforms in anticancer drug/nucleotide/protein delivery, cancer diagnosis, specific targeting, cancer vaccine, cancer treatments, evaluation of therapeutic responses, etc.

Prof. Dr. Lisheng Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • cancer markers
  • drug delivery
  • cancer therapy
  • immunotherapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2704 KiB  
Article
Engineering Biomimetic Nanoparticles through Extracellular Vesicle Coating in Cancer Tissue Models
by Gema Quiñonero, Juan Gallo, Alex Carrasco, Josep Samitier and Aranzazu Villasante
Nanomaterials 2023, 13(24), 3097; https://doi.org/10.3390/nano13243097 - 07 Dec 2023
Viewed by 999
Abstract
Using nanoparticles (NPs) in drug delivery has exhibited promising therapeutic potential in various cancer types. Nevertheless, several challenges must be addressed, including the formation of the protein corona, reduced targeting efficiency and specificity, potential immune responses, and issues related to NP penetration and [...] Read more.
Using nanoparticles (NPs) in drug delivery has exhibited promising therapeutic potential in various cancer types. Nevertheless, several challenges must be addressed, including the formation of the protein corona, reduced targeting efficiency and specificity, potential immune responses, and issues related to NP penetration and distribution within 3-dimensional tissues. To tackle these challenges, we have successfully integrated iron oxide nanoparticles into neuroblastoma-derived extracellular vesicles (EVs) using the parental labeling method. We first developed a tissue-engineered (TE) neuroblastoma model, confirming the viability and proliferation of neuroblastoma cells for at least 12 days, supporting its utility for EV isolation. Importantly, EVs from long-term cultures exhibited no differences compared to short-term cultures. Concurrently, we designed Rhodamine (Rh) and Polyacrylic acid (PAA)-functionalized magnetite nanoparticles (Fe3O4@PAA-Rh) with high crystallinity, purity, and superparamagnetic properties (average size: 9.2 ± 2.5 nm). We then investigated the internalization of Fe3O4@PAA-Rh nanoparticles within neuroblastoma cells within the TE model. Maximum accumulation was observed overnight while ensuring robust cell viability. However, nanoparticle internalization was low. Taking advantage of the enhanced glucose metabolism exhibited by cancer cells, glucose (Glc)-functionalized nanoparticles (Fe3O4@PAA-Rh-Glc) were synthesized, showing superior cell uptake within the 3D model without inducing toxicity. These glucose-modified nanoparticles were selected for parental labeling of the TE models, showing effective NP encapsulation into EVs. Our research introduces innovative approaches to advance NP delivery, by partially addressing the challenges associated with 3D systems, optimizing internalization, and enhancing NP stability and specificity through EV-based carriers. Also, our findings hold the promise of more precise and effective cancer therapies while minimizing potential side effects. Full article
(This article belongs to the Special Issue Nanomedicine in Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 5529 KiB  
Review
Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination
by Victoria Ainsworth, Michele Moreau, Romy Guthier, Ysaac Zegeye, David Kozono, William Swanson, Marian Jandel, Philmo Oh, Harry Quon, Robert F. Hobbs, Sayeda Yasmin-Karim, Erno Sajo and Wilfred Ngwa
Nanomaterials 2023, 13(12), 1844; https://doi.org/10.3390/nano13121844 - 12 Jun 2023
Viewed by 2073
Abstract
Recent studies have highlighted the potential of smart radiotherapy biomaterials (SRBs) for combining radiotherapy and immunotherapy. These SRBs include smart fiducial markers and smart nanoparticles made with high atomic number materials that can provide requisite image contrast during radiotherapy, increase tumor immunogenicity, and [...] Read more.
Recent studies have highlighted the potential of smart radiotherapy biomaterials (SRBs) for combining radiotherapy and immunotherapy. These SRBs include smart fiducial markers and smart nanoparticles made with high atomic number materials that can provide requisite image contrast during radiotherapy, increase tumor immunogenicity, and provide sustained local delivery of immunotherapy. Here, we review the state-of-the-art in this area of research, the challenges and opportunities, with a focus on in situ vaccination to expand the role of radiotherapy in the treatment of both local and metastatic disease. A roadmap for clinical translation is outlined with a focus on specific cancers where such an approach is readily translatable or will have the highest impact. The potential of FLASH radiotherapy to synergize with SRBs is discussed including prospects for using SRBs in place of currently used inert radiotherapy biomaterials such as fiducial markers, or spacers. While the bulk of this review focuses on the last decade, in some cases, relevant foundational work extends as far back as the last two and half decades. Full article
(This article belongs to the Special Issue Nanomedicine in Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop